All Moderna articles
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
NewsBillionaire professor donates ‘transformative’ sum to protein science institute
$210 million endowment from entrepreneur and Moderna investor Tim Springer will support ongoing research
-
BusinessModerna sued over Covid-19 vaccine-related patents
Arbutus and Genevant say lipid nanoparticles that protect mRNA infringe six key patents
-
BusinessTrials start of mRNA vaccine for HIV
First steps towards protection from the many and variable viral strains
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessUS grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
-
BusinessOxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
BusinessModerna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
BusinessEncouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
BusinessRNA vaccines are coronavirus frontrunners
Several groups have potential Sars-CoV-2 vaccines ready or close to testing, thanks to rapid development pathways
-
Business
AstraZeneca partners with Moderna for $240 million
Pharma company sheds more jobs and backs messenger RNA therapeutics